Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Completed 73Unknown 38Terminated 8Withdrawn 5Active not recruiting 5Recruiting 2Approved for marketing 2Suspended 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 5NSCLC 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1EGFR-mutant Non-small Cell Lung Cancer 1

Interventions

Carboplatin 85pembrolizumab 78Pemetrexed 68Cisplatin 56Paclitaxel 45osimertinib 41Nivolumab 40durvalumab 37Docetaxel 33atezolizumab 20Gemcitabine 18Radiotherapy 17Radiosurgery 16amivantamab 15Ipilimumab 15130-nm albumin-bound paclitaxel 14Taxes 13Specimen Handling 12Magnetic Resonance Spectroscopy 12Crizotinib 11lazertinib 9Radiation 9Immunoglobulin G 9Drug Therapy 9Disulfides 9Bevacizumab 9tislelizumab 8cemiplimab 8alectinib 8Erlotinib Hydrochloride 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Non-Small-Cell Lung × Gefitinib × Clear all
NCT03122717 2026-04-29

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Dana-Farber Cancer Institute

Phase 1/2 Active not recruiting
48 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03040973 2026-04-02

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Novartis

Phase 2 Active not recruiting
29 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02411448 2026-01-16

RELAY

Eli Lilly and Company

Phase 3 Active not recruiting
545 enrolled 24 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03944772 2025-01-30

ORCHARD

AstraZeneca

Phase 2 Active not recruiting
247 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04143607 2024-06-14

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
337 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡